Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C

Digestive and Liver Disease

Volumn 45, Issue 6, 2013, Pages 510-515

  Wang, Jing Houng ^a   Kuo, Yuan Hung ^a   Wang, Chih Chi ^a   Chen, Chao Long ^a   Cheng, Yu Fen ^a   Hsu, Hsuan Chih ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

BCLC stage C; Child Pugh class A; Hepatocellular carcinoma; Sorafenib; Surgical resection

Indexed keywords

SORAFENIB;

ABLATION THERAPY; ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR INVASION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME;

EID: 84878158948     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.10.019     Document Type: Article

References (25)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005, 55:74-108.
2. Befeler A.S., Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-1619.
3. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Bosch F.X., Ribes J., Díaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
5. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
6. Bruix J., Sherman M. Management of hepatocellular carcinoma-an update. Hepatology 2011, 53:1020-1022.
7. Kuo Y.H., Lu S.N., Chen C.L., et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. European Journal of Cancer 2010, 46:744-751.
8. Bruix J., Sherman M., Llovet J.M., et al. EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology 2001, 35:421-430.
9. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 1999, 19:329-338.
10. Bruix J., Sherman M. Practice Guidelines Committee American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
11. Villanueva A., Newell P., Chiang D.Y., et al. Genomics and signaling pathways in hepatocellular carcinoma. Seminars in Liver Disease 2007, 27:55-76.
12. Semela D., Dufour J.F. Angiogenesis and hepatocellular carcinoma. Journal of Hepatology 2004, 41:864-880.
13. Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 2006, 66:11851-11858.
14. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359:378-390.
15. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009, 10:25-34.
16. Wang J.H., Changchien C.S., Hu T.H., et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - survival analysis of 3892 patients. European Journal of Cancer 2008, 44:1000-1006.
17. Changchien C.S., Chen C.L., Yen Y.H., et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. Journal of Gastroenterology 2008, 43:159-170.
18. Cheng Y.F., Kan Z., Chen C.L., et al. Efficacy and safety of preoperative lobar or segmental ablation via transarterial administration of Ethiodol and ethanol mixture for treatment of hepatocellular carcinoma: clinical study. World Journal of Surgery 2000, 24:844-850.
19. Poon D., Anderson B.O., Chen L.T., et al. Asian oncology summit, 2009. Lancet Oncology 2009, 10:1111-1118.
20. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008, 75:1-12.
21. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000, 32:1224-1229.
22. Chan A.O., Yuen M.F., Hui C.K., et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002, 94:1747-1752.
23. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine 1998, 17:2265-2281.
24. Lopez P.M., Villanueva A., Llovet J.M. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Alimentary Pharmacology and Therapeutics 2006, 23:1535-1547.
25. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.